British journal of clinical pharmacology · 2026
Utilization of immune checkpoint inhibitors for the treatment of cancer in Scotland, 2018-2024: A national retrospective cohort study.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Mueller Tanja, Crearie Christine, Lu Liya, Pan Jiafeng, Sneden Fraser N, Martin David, Kurdi Amanj, Thomson Catherine S, Clarke Julie, Bennie Marion
Аннотация
AIMS: The aim of the study is to describe the use of immune checkpoint inhibitors (ICIs) for the treatment of cancer in Scotland.
METHODS: The retrospective observational cohort study included patients aged 18 years or older who commenced treatment with an ICI in Scotland between 1 January 2018 and 31 December 2024. The National Systemic Anti-Cancer Therapy (SACT) dataset was used to identify patients and obtain details on ICI treatments and patient characteristics. Additional data sources providing information on comorbidities were linked deterministically via a unique patient identifier. All analyses were descriptive.
RESULTS: In total, 10 394 patients in Scotland initiated their first ICI treatment between 2018 and 2024; the number of patients initiating ICIs increased substantially year-on-year, from 764 patients in 2018 to 2233 patients in 2024. The most commonly prescribed ICI was pembrolizumab (56.8%, n = 5908), followed by nivolumab (16.4%, n = 1700) and atezolizumab (11.3%, n = 1170); treatment was most commonly initiated for lung and chest cancers (44.1%, n = 4585), skin cancer (18.8%, n = 1955) and urological cancers (14.8%, n = 1539). While the majority of patients (66.6%, n = 6923) initiated ICI monotherapy, combination therapies-most commonly ICI with chemotherapy (18.4%, n = 1910)-were also used. Overall, 6.6% of patients (n = 681) were on treatment for more than 2 years.
CONCLUSIONS: With the continuous addition of new ICIs, alongside the ever-expanding list of approved indications for their use, the observed increase in ICI use is expected to continue. This increasing use of ICIs may pose challenges to health services-for instance, an increase in immune-related adverse effects-with potential implications for clinical practice and future research.
METHODS: The retrospective observational cohort study included patients aged 18 years or older who commenced treatment with an ICI in Scotland between 1 January 2018 and 31 December 2024. The National Systemic Anti-Cancer Therapy (SACT) dataset was used to identify patients and obtain details on ICI treatments and patient characteristics. Additional data sources providing information on comorbidities were linked deterministically via a unique patient identifier. All analyses were descriptive.
RESULTS: In total, 10 394 patients in Scotland initiated their first ICI treatment between 2018 and 2024; the number of patients initiating ICIs increased substantially year-on-year, from 764 patients in 2018 to 2233 patients in 2024. The most commonly prescribed ICI was pembrolizumab (56.8%, n = 5908), followed by nivolumab (16.4%, n = 1700) and atezolizumab (11.3%, n = 1170); treatment was most commonly initiated for lung and chest cancers (44.1%, n = 4585), skin cancer (18.8%, n = 1955) and urological cancers (14.8%, n = 1539). While the majority of patients (66.6%, n = 6923) initiated ICI monotherapy, combination therapies-most commonly ICI with chemotherapy (18.4%, n = 1910)-were also used. Overall, 6.6% of patients (n = 681) were on treatment for more than 2 years.
CONCLUSIONS: With the continuous addition of new ICIs, alongside the ever-expanding list of approved indications for their use, the observed increase in ICI use is expected to continue. This increasing use of ICIs may pose challenges to health services-for instance, an increase in immune-related adverse effects-with potential implications for clinical practice and future research.